Skip to main content
. 2017 Apr 5;38(5):541–551. doi: 10.1093/carcin/bgx033

Table 2.

Stratification analysis of the three identified SNPs by histological types and smoking status

SNP Impa Overall Adenocarcinoma Squamous cell carcinoma Never smoking Ever smoking
OR (95% CI)b P b OR (95% CI)b P b OR (95% CI)b P b OR (95% CI)b P b OR (95% CI)b P b
rs17781739
 ICR 0.97 0.96 (0.88–1.04) 0.287 1.01 (0.87–1.17) 0.880 0.94 (0.83–1.08) 0.397 NA NA NA NA
 MDACC 0.92 0.95 (0.82–1.09) 0.426 0.97 (0.82–1.15) 0.745 0.86 (0.69–1.07) 0.164 NA NA 0.95 (0.82–1.09) 0.426
 IARC 0.92 0.93 (0.85–1.01) 0.088 0.95 (0.82–1.11) 0.524 0.98 (0.87–1.10) 0.726 0.78 (0.59–1.04) 0.089 0.93 (0.85–1.02) 0.131
 NCI 0.97 0.88 (0.83–0.93) 2.00E−05 0.88 (0.81–0.96) 2.60E−03 0.84 (0.77–0.92) 2.14E−04 0.86 (0.69–1.05)4 0.1544 0.89 (0.83–0.95) 5.31E−04
 Toronto 0.94 0.88 (0.68–1.12) 0.300 0.67 (0.46–0.99) 0.043 1.05 (0.63–1.76) 0.841 0.89 (0.58–1.36) 0.579 0.85 (0.62–1.16) 0.308
 GLC 0.95 0.93 (0.76–1.13) 0.455 0.86 (0.66–1.14) 0.302 1.04 (0.74–1.46) 0.836 0.81 (0.42–1.55) 0.522 0.95 (0.74–1.23) 0.714
 Harvard 0.97 0.99 (0.91–1.07) 0.752 0.93 (0.81–1.06) 0.254 1.15 (0.95–1.39) 0.141 1.49 (0.96–2.31) 0.075 1.02 (0.88–1.20) 0.767
 Decode 0.95 1.11 (0.95–1.30) 0.202 1.11 (0.93–1.32) 0.256 1.17 (0.89–1.53) 0.273 NA NA NA NA
 Meta- analysisc 0.94 (0.90–0.99) 0.012 0.94 (0.88–1.01) 0.070 0.96 (0.88–1.06) 0.441 0.89 (0.77–1.03) 0.112 0.92 (0.88–0.96) 3.31E−04
rs12587742
 ICR 0.93 1.12 (1.02–1.24) 0.016 1.07 (0.9–1.28) 0.423 1.06 (0.91–1.24) 0.453 NA NA NA NA
 MDACC 0.89 1.18 (1.01–1.39) 0.043 1.27 (1.05–1.53) 0.015 1.05 (0.82–1.36) 0.698 NA NA 1.18 (1.01–1.39) 0.043
 IARC 0.90 1.11 (1.01–1.22) 0.033 1.10 (0.93–1.31) 0.273 1.18 (1.03–1.35) 0.015 1.15 (0.85–1.56) 0.356 1.14 (1.02–1.27) 0.019
 NCI 0.94 1.07 (1.00–1.14) 0.050 1.04 (0.95–1.15) 0.370 1.16 (1.05–1.29) 0.005 0.88 (0.69–1.13)d 0.331d 1.03 (0.96–1.11) 0.394
 Toronto 0.90 0.88 (0.68–1.15) 0.364 0.99 (0.65–1.50) 0.965 0.79 (0.47–1.33) 0.377 0.62 (0.38–1.01) 0.054 1.06 (0.76–1.48) 0.746
 GLC 0.92 1.19 (0.94–1.51) 0.143 1.24 (0.91–1.70) 0.174 0.90 (0.59–1.37) 0.631 1.46 (0.75–2.83) 0.266 1.12 (0.82–1.53) 0.467
 Harvard 0.95 1.08 (0.98–1.19) 0.137 1.15 (0.98–1.34) 0.078 1.29 (1.03–1.61) 0.026 1.14 (0.72–1.81) 0.579 0.90 (0.76–1.07) 0.246
 Decode 0.91 0.90 (0.76–1.07) 0.235 0.90 (0.74–1.10) 0.310 0.84 (0.62–1.15) 0.283 NA NA NA NA
 Meta- analysisc 1.08 (1.04–1.12) 8.15E−05 1.08 (1.02–1.15) 0.010 1.12 (1.05–1.20) 4.16E−04 0.97 (0.76–1.25) 0.840 1.05 (0.98–1.13) 0.163
rs2240980
 ICR 0.99 1.11 (1.02–1.20) 0.012 1.16 (1.00–1.34) 0.052 1.04 (0.91–1.18) 0.599 NA NA NA NA
 MDACC 0.95 1.14 (1.00–1.31) 0.048 1.20 (1.03–1.41) 0.021 0.99 (0.80–1.22) 0.932 NA NA 1.14 (1.00–1.31) 0.048
 IARC 0.96 1.10 (1.02–1.20) 0.017 1.09 (0.94–1.27) 0.254 1.14 (1.02–1.29) 0.026 1.32 (1.02–1.72) 0.035 1.10 (1.00–1.20) 0.046
 NCI 0.99 1.07 (1.01–1.13) 0.025 1.07 (0.99–1.16) 0.101 1.11 (1.01–1.21) 0.030 1.11 (0.90–1.35)4 0.325d 1.03 (0.97–1.10) 0.317
 Toronto 0.97 0.94 (0.74–1.18) 0.583 1.01 (0.70–1.44) 0.968 0.77 (0.49–1.21) 0.249 0.82 (0.54–1.23) 0.329 1.00 (0.74–1.33) 0.979
 GLC 0.98 1.08 (0.88–1.33) 0.455 1.10 (0.83–1.44) 0.506 0.88 (0.61–1.27) 0.496 1.17 (0.64–2.17) 0.607 1.04 (0.80–1.36) 0.756
 Harvard 0.98 1.08 (0.99–1.17) 0.087 1.15 (1.01–1.31) 0.036 1.07 (0.89–1.29) 0.481 0.87 (0.58–1.31) 0.505 0.99 (0.86–1.15) 0.933
 Decode 0.98 0.96 (0.83–1.11) 0.566 0.96 (0.82–1.13) 0.640 0.92 (0.71–1.20) 0.554 NA NA NA NA
 Meta- analysisc 1.08 (1.04–1.11) 1.08E−05 1.10 (1.04–1.15) 3.44E−04 1.07 (1.01–1.13) 0.017 1.08 (0.87–1.34) 0.481 1.05 (0.99–1.11) 0.127

Imp, imputation; Harvard, Harvard Lung Cancer Study, US; deCODE, Icelandic Lung Cancer Study, Iceland.

aImputation quality score: r-squared from MACH for the MDACC, IARC, GLC and Harvard studies; info values from IMPUTE2 were used in other studies.

bAdjusted for the top significant principle components for each study.

cFixed effects model was used in the meta-analysis if Q-test P > 0.1 and heterogeneity statistic I2 < 25%; otherwise random effects model.

dThe pooling results of the four NCI sub-studies: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II Nutrition Cohort (CPS-II), the Environment and Genetics in Lung Cancer Etiology (EAGLE) and the Prostate, Lung, Colon, Ovary Screening Trial (PLCO). The detailed results for each sub-study were presented in Figure 3.